I. Brunetti
About
I. Brunetti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology.
According to data from OpenAlex, I. Brunetti has authored 65 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 13 papers in Hepatology. Recurrent topics in I. Brunetti's work include Colorectal Cancer Treatments and Studies (30 papers), Cancer Treatment and Pharmacology (26 papers) and Hepatocellular Carcinoma Treatment and Prognosis (13 papers). I. Brunetti is often cited by papers focused on Colorectal Cancer Treatments and Studies (30 papers), Cancer Treatment and Pharmacology (26 papers) and Hepatocellular Carcinoma Treatment and Prognosis (13 papers). I. Brunetti collaborates with scholars based in Italy, United States and United Kingdom. I. Brunetti's co-authors include Alfredo Falcone, Gianluca Masi, E. Pfanner, Giacomo Allegrini, M. Andreuccetti, Pierfranco Conté, Sergio Ricci, Samanta Cupini, V. Picone and Giovanni Benedetti and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.
In The Last Decade
I. Brunetti
65 papers receiving 2.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| I. Brunetti Italy | 21 | 1.8k | 892 | 623 | 573 | 438 | 65 | 2.4k | ||
| Maurizio Cosimelli Italy | 27 | 1.6k 0.9× | 290 0.3× | 562 0.9× | 1.1k 2.0× | 422 1.0× | 103 | 2.5k | ||
| Robert Stagg United States | 24 | 1.4k 0.8× | 705 0.8× | 624 1.0× | 436 0.8× | 824 1.9× | 61 | 3.3k | ||
| David Gallagher Ireland | 19 | 774 0.4× | 170 0.2× | 514 0.8× | 537 0.9× | 494 1.1× | 101 | 1.7k | ||
| Isabel Chirivella Spain | 16 | 1.1k 0.6× | 258 0.3× | 453 0.7× | 207 0.4× | 246 0.6× | 53 | 1.5k | ||
| Rut Isacson Israel | 10 | 1.3k 0.7× | 205 0.2× | 441 0.7× | 340 0.6× | 378 0.9× | 22 | 1.9k | ||
| Skye Hongiun Cheng Taiwan | 23 | 562 0.3× | 410 0.5× | 420 0.7× | 568 1.0× | 269 0.6× | 32 | 1.7k | ||
| Pavlos Papakostas Greece | 26 | 1.5k 0.9× | 133 0.1× | 841 1.3× | 448 0.8× | 439 1.0× | 104 | 2.2k | ||
| Jane Robertson United Kingdom | 22 | 1.3k 0.7× | 225 0.3× | 510 0.8× | 92 0.2× | 816 1.9× | 57 | 2.0k | ||
| C.-H. Köhne Germany | 20 | 1.6k 0.9× | 670 0.8× | 608 1.0× | 427 0.7× | 300 0.7× | 48 | 2.1k | ||
| Osama E. Rahma United States | 28 | 2.1k 1.2× | 271 0.3× | 520 0.8× | 315 0.5× | 485 1.1× | 113 | 2.9k |
Countries citing papers authored by I. Brunetti
Since
Specialization
Citations
This map shows the geographic impact of I. Brunetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Brunetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Brunetti more than expected).
Fields of papers citing papers by I. Brunetti
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by I. Brunetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Brunetti. The network helps show where I. Brunetti may publish in the future.
Co-authorship network of co-authors of I. Brunetti
This figure shows the co-authorship network connecting the top 25 collaborators of I. Brunetti. A scholar is included among the top collaborators of I. Brunetti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Brunetti. I. Brunetti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Antoniotti, Carlotta, Federica Marmorino, Marzia Pennati, et al.. (2017). Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts). Annals of Oncology. 28. vi4–vi4.
2.
Cremolini, Chiara, Fotios Loupakis, Daniele Rossini, et al.. (2014). Folfoxiri with or Without Bevacizumab (Bev) As First-Line Treatment of Metastatic Colorectal Cancer (Mcrc): a Propensity Score-Based Analysis. Annals of Oncology. 25. iv175–iv175.
3.
Masi, Gianluca, Fotios Loupakis, Luca Emanuele Pollina, et al.. (2009). Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases. Annals of Surgery. 249(3). 420–425.
4.
Vasile, Enrico, Gianluca Masi, Lorenzo Fornaro, et al.. (2009). A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. British Journal of Cancer. 100(11). 1720–1724.
5.
Cipollini, Giovanna, Stefania Tommasi, Angelo Paradiso, et al.. (2004). Genetic alterations in hereditary breast cancer. Annals of Oncology. 15. i7–i13.
6.
Masi, Gianluca, Giacomo Allegrini, Samanta Cupini, et al.. (2004). First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Annals of Oncology. 15(12). 1766–1772.
7.
Barone, Carlo, Alessandra Cassano, Carmelo Pozzo, et al.. (2004). Long-Term Follow-Up of a Pilot Phase II Study with Neoadjuvant Epidoxorubicin, Etoposide and Cisplatin in Gastric Cancer. Oncology. 67(1). 48–53.
8.
Ghimenti, Chiara, Elisa Sensi, Silvano Presciuttini, et al.. (2002). Germline mutations of the BRCA1‐associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations. Genes Chromosomes and Cancer. 33(3). 235–242.
9.
Gadducci, Angiolo, F Carnino, S. Chiara, et al.. (2000). Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A Randomized Trial of the Gruppo Oncologico Nord-Ovest. Gynecologic Oncology. 76(2). 157–162.
10.
Falcone, Alfredo, Giacomo Allegrini, Monica Lencioni, et al.. (1999). Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study. Cancer Chemotherapy and Pharmacology. 44(2). 159–163.
11.
Falcone, Alfredo, E. Pfanner, Serafino Ricci, et al.. (1996). Treatment of metastatic renal cell carcinomawith constant-rate floxuridine infusion plus recombinant alpha 2b-interferon. Annals of Oncology.
12.
Caligo, Maria A., Chiara Ghimenti, Giovanna Cipollini, et al.. (1996). BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations.. Research Padua Archive (University of Padua). 13(7). 1483–8.
13.
Falcone, Alfredo, E. Pfanner, Romano Danesi, et al.. (1995). Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II Study. Cancer. 75(2). 440–443.
14.
Gadducci, Angiolo, et al.. (1994). Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. European Journal of Cancer. 30(10). 1432–1435.
15.
Falcone, Alfredo, et al.. (1993). Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma a phase I-II study. Cancer. 72(2). 564–568.
16.
Gadducci, Angiolo, I. Brunetti, Marco Bruzzone, et al.. (1992). Cisplatin-based combination chemotherapy with or without doxorubicin in advanced epithelial ovarian cancer: 8-year update of a randomized multicentric clinical trial. The Gruppo Oncologico Nord Ovest (GONO).. PubMed. 13(1 Suppl). 36–9.
17.
Bajetta, Emilio, B. Giannotti, Laura Brogelli, et al.. (1990). Phase II Study of Interferon α-2a and Dacarbazine in Advanced Melanoma. American Journal of Clinical Oncology. 13(5). 405–409.
18.
Posner, Marshall R., Peter A. Calabresi, I. Brunetti, et al.. (1990). Oral Zidovudine, Continuous-Infusion Fluorouracil, and Oral Leucovorin Calcium: A Phase I Study. JNCI Journal of the National Cancer Institute. 82(21). 1710–1714.
19.
Sertoli, M. R., M.G. Bernengo, Andrea Ardizzoni, et al.. (1989). Phase II Trial of Recombinant Alpha-2b Interferon in the Treatment of Metastatic Skin Melanoma. Oncology. 46(2). 96–98.
20.
Brunetti, I., Andrea Ardizzoni, Alfredo Falcone, et al.. (1989). Recombinant α-2a Interferon Plus Vinblastine in the Treatment of Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology. 12(1). 43–45.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Maurizio Cosimelli Breakdown of academic impact, for papers by Robert Stagg Breakdown of academic impact, for papers by David Gallagher Breakdown of academic impact, for papers by Isabel Chirivella Breakdown of academic impact, for papers by Rut Isacson Breakdown of academic impact, for papers by Skye Hongiun Cheng Breakdown of academic impact, for papers by Pavlos Papakostas Breakdown of academic impact, for papers by Jane Robertson Breakdown of academic impact, for papers by C.-H. Köhne Breakdown of academic impact, for papers by Osama E. Rahma